ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Reauthorization Bill Ready For Senate Floor; Report to Panel Makes Clear Why Renewal Needed

April 22, 1988

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

July 27, 2012

NCI-Approved Clinical Trials

July 29, 2005

NCI to Fund research In Tobacco Use Prevention In Youth

December 6, 1996

About Face; NCI To Keep Preclinical AIDS Drug Development

December 12, 1986

Also in this 8-page issue: Amendment strips funding from two NIHM grants. NCI will commit $7 million to begin restructuring its clinical trials system, Institute director says.

July 1, 2005